Screening of Fibrosing and/or Viral Chronic Hepatopathies in Jail (SNIFF11)
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Screening of Fibrosing and/or Viral Chronic Hepatopathies in Jail|
- Liver fibrosis evaluation [ Time Frame: D0 ] [ Designated as safety issue: No ]Evaluation of liver fibrosis with blood tests
|Study Start Date:||April 2007|
|Study Completion Date:||March 2008|
|Primary Completion Date:||March 2008 (Final data collection date for primary outcome measure)|
Other: liver fibrosis evaluation
Primary outcome: Screening of clinically significant fibrosis with FibroMeter blood score. Screening for hepatitis B and hepatitis C viruses.
Secondary outcome: Clinically significant fibrosis confirmed with FibroScan®.
The means for this study are a clinical questionnaire, a virological screening, a blood score for liver fibrosis: FibroMeter according to cause of the fibrosis and FibroScan® is referent and independent examination.
The expected results from this study are the knowledge of the prevalence of hepatopathies with hepatic fibrosis will be able to justify, possibly, a screening politic of them. This study will permit to evaluate the feasibility of noninvasive screening of the liver fibrosis in the goal to suppress the liver biopsy in a population having numerous drawbacks.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00453869
|University Hospital Angers|
|Angers, France, 49 933|
|Principal Investigator:||Paul CALES, MD, PhD||UH Angers|